Millennium Management
GPCR icon

Millennium Management’s Structure Therapeutics GPCR Stock Holding History

Millennium Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-38,600
Closed -$1.52M – 6234
2024
Q2 		$1.52M Buy
+38,600
New +$1.59M ﹤0.01% 3774
2024
Q1 		– Sell
-9,000
Closed -$367K – 6357
2023
Q4 		$367K Buy
+9,000
New +$516K ﹤0.01% 4836

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Millennium Management's GPCR Position: Q1 2026 in Review

Millennium Management increased its Structure Therapeutics (GPCR) stake by 11% in Q1 2026, buying an estimated $1.12M and bringing the position to 168,931 shares worth $8.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

Millennium Management first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $44.7M in Q2 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Millennium Management held 168,931 shares of Structure Therapeutics worth $8.14M as of Q1 2026.
  • Millennium Management bought 16,371 Structure Therapeutics shares in Q1 2026, an estimated $1.12M.
  • Structure Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2379 holding.
  • Millennium Management first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Millennium Management's Structure Therapeutics position peaked at $44.7M in Q2 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.